Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jul 01, 2015 10:52am
123 Views
Post# 23884153

RE:RE:RE:RE:RE:RE:RE:O.T.- BTI board

RE:RE:RE:RE:RE:RE:RE:O.T.- BTI boardDisclaimer: If you don't care about BiOasis (BTI), please disregard.

SanFran,

You and I see eye to eye on most things RVX. But in this case of BTI (BiOasis) I must disagree and correct some of your misleading statements that may give others a false impresion of BTI.

BiOasis (BTI; https://www.bioasis.ca/) is a small cap Biotech in Richmond, BC that specializes in technolgies to assist in small molecules crossing the blood brain barrier. This is a HUGE market. Equal to if not bigger than the market for RVX. While there are many other cardiovascular drugs out there, there is nothing out there approved to help drugs cross the blood brain barrier. BTI is for real. You say you've done research on BTI. Have you been to their website? Have you read their company update lately (https://www.bioasis.ca/2015/05/12/bioasis-provides-scientific-updates-on-its-transcend-programs/). Their technolgy is based on attaching a peptide (Transcendpep) to fusion proteins (antibody therapies, enzyme replacement therapies), siRNAs (to silence genes) or any drug, and this Transcendpep (which is a short peptide of a much larger melanotransferring protein) uses mother nature's own receptor mediated endocytosis to ferry the cargo across the blood brain barrier. They also just received a research grant to evaluate an entire different blood brain barrier crossing technology (https://www.bioasis.ca/2015/05/27/bioasis-enters-into-a-collaborative-research-and-joint-funding-support-agreement-entitled-focus-on-brain/).

Penny stock has kind of a bad ring to it.  JDStox is still active on the BTI board, but only makes a rare appearance on the RVX board nowadays. JDStox has openly shared his identity and contact info and has nothing to hide. In fact, I just talked to him on the phone last week about BTI. The guy knows his stuff. If you want to know why he stopped posting on RVX, contact him. He has given his reasons before why he favors BTI vs. RVX in the short term. Kayaker BC is also still an active contributor to the BTI board. I highly respect both KayakerBC and JDStox.

In terms of RVX popping and BTI not......its apples and organges. We all know about the past history of RVX and how right now RVX is banking on one molecule (RVX-208) and how endpoints have been missed, mechanism of action has been revised, trials have been re-analyzed, endpoints have evolved, patient population has been revised. BTI decided to stop using the much larger melanotransferrin protein (Transcend) and instead refine and develop a series of peptides based on Transcend (Transcendpeps) that are just as effective (if not more), but cheaper to produce, more stable, and more amenable to attachign to small molecules as either a fusion protein or covalently attached. They are geared towards doing a number of licensing deals and imminently ready to enter this commercialization phase. In terms of human clinical trials, they will be filing an IND in 2016 for HER2+ brain cancer treatment (https://biotuesdays.com/2015/06/23/bioasis-to-file-ind-for-her2-brain-cancer-treatment-in-2016/). This is a human trial using a fusion protein Herceptin-antibody fused to Transcendpep. However, this is just ONE of countless applications of Transcendpep because it can be fused to any number of fusion protein antibody or enzyme replacment therapies, linked to any drug that is desired to cross the BBB, and also shuttle siRNAs across the blood brain barrier to silence genes. They have SOLID animal model data for all of these applicitions.

So please don't bad-mouth BiOasis by calling them a penny stock and a potential scam. Anyone interested in BiOasis can go to the BTI board and learn a lot more. But BTI shouldn't be discussed here anymore. I provided this length post just to correct the mis-representations that were posted earlier. Whether BiOasis or RVX has a homerun "pop" first is not my point here. I am not going to weigh in on that. I own about equal shares of both. I have my own opinion of which may pop first, but to each his/her own. I think they both have a great chance to be blockbuster drugs (RVX-208) and technologies (Transcendpep).

Best,

BearDownAZ


 
 
 
Bullboard Posts